Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
boston blog main
boston top stories
clinical trials
6
×
life sciences
national blog main
national top stories
6
×
new york blog main
new york top stories
6
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
fda
indiana blog main
indiana top stories
national
new york
nonalcoholic steatohepatitis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
akcea therapeutics
avexis
biotech
bristol-myers squibb
cancer
cancer immunotherapy
geoffrey porges
intercept pharmaceuticals
What
disease
6
×
approved
drug
fda
nash
akcea
fatty
known
liver
new
news
patients
roundup
treatment
according
acorda
ago
alnylam
american
amyloidosis
ash
attr
available
battle
big
bio
biotech
blood
cases
centers
cigarettes
companies
control
cope
country
data
deaths
debilitating
diego
digital
Language
unset
Current search:
disease
×
photo
×
" national top stories "
×
" clinical trials "
×
" new york top stories "
×
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On